The multikinase inhibitor sorafenib is currently the treatment of reference for advanced
hepatocellular carcinoma (HCC). In our report, we examined the cytotoxic effects of sorafenib on …

Sorafenib is the treatment of reference for advanced hepatocellular carcinoma (HCC), the
most frequent form of primary liver tumour. The loss of function of the retinoblastoma (Rb) …

Sorafenib is currently the medical treatment of reference for hepatocellular carcinoma (HCC),
but it is not known whether sorafenib is equally active in all HCC. Here, our aim was to …

Background Sorafenib, a kinase inhibitor active against various solid tumours, induces oxidative
stress and ferroptosis, a new form of oxidative necrosis, in some cancer cells. Clinically-…

Strontium ranelate exerts both an anticatabolic and an anabolic effect on bone cells. To
further investigate the mechanism by which strontium ranelate inhibits bone resorption, the …

Background. Patients with chronic kidney disease (CKD) develop various bone abnormalities
characterized by impaired bone remodelling. Recent data suggest that accumulation of the …

Sorafenib is the first line treatment for advanced hepatocellular carcinoma (HCC). We explored
its impact on the proteostasis of cancer cells, ie the processes that regulate the synthesis, …

Ferroptosis, a regulated form of cell necrosis was previously reported to be induced upon
pharmacological targeting of the cystine transporter SLC7A11 in Head and neck Squamous …

Proteins of the BCL2 family are key regulators of apoptosis. Their expression levels are
frequently altered in cancers, enabling tumor cells to survive. To gain insight into the …

Chronic kidney disease (CKD) has recently emerged as a major risk factor for cardiovascular
pathology. CKD patients display accelerated atherosclerotic process, leading to circulatory …